Format
Items per page
Sort by

Send to:

Choose Destination

Results: 14

Related Articles by Review for PubMed (Select 23241423)

1.

Thromboembolic risks of recombinant factor VIIa Use in warfarin-associated intracranial hemorrhage: a case-control study.

H-Y CS, Xuemei C, G KR, M BL, V HG, A SF, K FS.

BMC Neurol. 2012 Dec 15;12:158. doi: 10.1186/1471-2377-12-158.

2.

Off-label use of recombinant factor VIIa for treatment of haemorrhage: results from randomized clinical trials.

Johansson PI.

Vox Sang. 2008 Jul;95(1):1-7. doi: 10.1111/j.1423-0410.2008.01063.x. Epub 2008 Apr 23. Review.

PMID:
18435677
3.

Risk of thromboembolic complications after intracerebral hemorrhage according to ethnicity.

Christensen MC, Dawson J, Vincent C.

Adv Ther. 2008 Sep;25(9):831-41. doi: 10.1007/s12325-008-0092-0. Review.

PMID:
18777016
4.

Coagulopathic patients with traumatic intracranial bleeding: defining the role of recombinant factor VIIa.

Bartal C, Freedman J, Bowman K, Cusimano M.

J Trauma. 2007 Oct;63(4):725-32. Review.

PMID:
18089997
5.

Race against the clock: overcoming challenges in the management of anticoagulant-associated intracerebral hemorrhage.

Le Roux P, Pollack CV Jr, Milan M, Schaefer A.

J Neurosurg. 2014 Aug;121 Suppl:1-20. doi: 10.3171/2014.8.paradigm. Review.

PMID:
25081496
6.

Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia.

Simpson E, Lin Y, Stanworth S, Birchall J, Doree C, Hyde C.

Cochrane Database Syst Rev. 2012 Mar 14;3:CD005011. doi: 10.1002/14651858.CD005011.pub4. Review.

PMID:
22419303
7.

Methods to decrease blood loss and transfusion requirements for liver transplantation.

Gurusamy KS, Pissanou T, Pikhart H, Vaughan J, Burroughs AK, Davidson BR.

Cochrane Database Syst Rev. 2011 Dec 7;(12):CD009052. doi: 10.1002/14651858.CD009052.pub2. Review.

PMID:
22161443
8.

Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia.

Lin Y, Stanworth S, Birchall J, Doree C, Hyde C.

Cochrane Database Syst Rev. 2011 Feb 16;(2):CD005011. doi: 10.1002/14651858.CD005011.pub3. Review. Update in: Cochrane Database Syst Rev. 2012;3:CD005011.

PMID:
21328270
9.

Recombinant activated factor VIIa for the treatment of bleeding in major abdominal surgery including vascular and urological surgery: a review and meta-analysis of published data.

von Heymann C, Jonas S, Spies C, Wernecke KD, Ziemer S, Janssen D, Koscielny J.

Crit Care. 2008;12(1):R14. doi: 10.1186/cc6788. Epub 2008 Feb 15. Review.

10.

Recombinant FVIIa in the treatment of warfarin bleeding.

Berntorp E.

Semin Thromb Hemost. 2000;26(4):433-5. Review.

PMID:
11092220
11.

Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications.

Yank V, Tuohy CV, Logan AC, Bravata DM, Staudenmayer K, Eisenhut R, Sundaram V, McMahon D, Olkin I, McDonald KM, Owens DK, Stafford RS.

Ann Intern Med. 2011 Apr 19;154(8):529-40. doi: 10.7326/0003-4819-154-8-201104190-00004. Review.

12.

Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia.

Stanworth SJ, Birchall J, Doree CJ, Hyde C.

Cochrane Database Syst Rev. 2007 Apr 18;(2):CD005011. Review. Update in: Cochrane Database Syst Rev. 2011;(2):CD005011.

PMID:
17443565
13.

Clinical usefulness of recombinant activated factor VII in patients with liver failure undergoing invasive procedures.

Krisl JC, Meadows HE, Greenberg CS, Mazur JE.

Ann Pharmacother. 2011 Nov;45(11):1433-8. doi: 10.1345/aph.1Q207. Epub 2011 Oct 18. Review.

PMID:
22009992
14.

Thrombotic events in neonates receiving recombinant factor VIIa or fresh frozen plasma.

Puetz J, Darling G, Brabec P, Blatny J, Mathew P.

Pediatr Blood Cancer. 2009 Dec;53(6):1074-8. doi: 10.1002/pbc.22160. Review.

PMID:
19621430
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk